Pharmaceutical Commerce, January 2012
Demand for generic medicines is expected to reach $400 to $450 billion by 2015, with nearly 70 percent of this demand coming from the pharmerging economies. Alan Sheppard shares his insight on the major drivers of growth for the global generics market.
Pharmaceutical Commerce, October 2011
The number of patients suffering from diabetes continues to rise and at an alarming rate. Driven by the urgency and need to innovate, new therapies, including the introduction of non-insulin anti-diabetic medications, are delivering breakthrough treatment options to patients, providers, and payers.
Emerging Strategies: Faced with Change, Pharmaceutical Firms Shift Business Mix to Generics and Emerging Markets
Chemical & Engineering News, October 2011
Between now and 2015, about $138 billion in drug sales across eight major developed markets will be at risk to generic competition. Multinational pharmaceutical companies are looking to generic products and emerging markets, and much is riding on how well they balance their new and old businesses.
IMS White Paper, 2011
Rapid growth and rich potential vie with complex challenges in the APAC markets as government pressure on pricing intensifies. With an eye on revealing the real opportunities, our periodical considers the price/volume dilemma playing out in APAC, the implications of Taiwan’s health insurance reforms, and the growing importance of the pharmacy channel in Malaysia.
Pharmaceutical Commerce, September/October 2010
How the pharmaceutical industry and payers can work together to achieve cost savings and better health outcomes for patients.
Forum for Health Economics and Policy, July 2010
Biologics comprise a substantial — and likely growing — part of the branded pharmaceutical market. IMS’s Murray Aitken, along with Mark Trusheim and Ernst Berndt of MIT’s Sloan School of Management, compare the clinical and commercial characteristics of biologics and small molecule therapies.
Through in-depth, global analyses of more than 40 key therapeutic areas, covering 80% of pharmaceutical market value, we’re applying our specialized, forward-looking knowledge of disease market opportunity to a range of industry issues.
Declining growth in primary care requires radical new approaches to achieve greater value from the global market. In an InVivo Executive Summary, our senior market experts consider possibilities for reversing the current trend and why a “whole product” strategy may be the best way forward.